Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial

被引：0
|
作者：
Ohba, Akihiro
Morizane, Chigusa
Kawamoto, Yasuyuki
Komatsu, Yoshito
Ueno, Makoto
Kobayashi, Satoshi
Ikeda, Masafumi
Sasaki, Mitsuhito
Furuse, Junji
Okano, Naohiro
Hiraoka, Nobuyoshi
Yoshida, Hiroshi
Kuchiba, Aya
Sadachi, Ryo
Nakamura, Kenichi
Matsui, Naoko
Nakamura, Yoshiaki
Okamoto, Wataru
Yoshino, Takayuki
Okusaka, Takuji
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hokkaido Univ Hosp, Sapporo, Japan
[3] Kanagawa Canc Ctr, Yokohama, Japan
[4] Natl Canc Ctr Hosp East, Kashiwa, Japan
[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[6] Kyorin Univ, Fac Med, Tokyo, Japan
[7] Hiroshima Univ Hosp, Hiroshima, Japan
[8] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4097
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer
    Hsieh, Y. Pei
    ANNALS OF ONCOLOGY, 2024, 35 : S1394 - S1394
  • [2] Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial
    Ohba, Akihiro
    Morizane, Chigusa
    Ueno, Makoto
    Kobayashi, Satoshi
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Okano, Naohiro
    Furuse, Junji
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Sadachi, Ryo
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    FUTURE ONCOLOGY, 2022,
  • [3] Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial
    Ohba, Akihiro
    Morizane, Chigusa
    Ueno, Makoto
    Kobayashi, Satoshi
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Okano, Naohiro
    Furuse, Junji
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Sadachi, Ryo
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    FUTURE ONCOLOGY, 2022, 18 (19) : 2351 - 2360
  • [4] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
    Ohba, Akihiro
    Morizane, Chigusa
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ueno, Makoto
    Kobayashi, Satoshi
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Furuse, Junji
    Okano, Naohiro
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Sadachi, Ryo
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Saura Manich, C.
    Modi, S.
    Krop, I.
    Park, Y. H.
    Kim, S-B.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Singh, J.
    Yamashita, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
  • [6] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)
    Oh, Do-Youn
    Lugowska, Iwona A.
    Stroyakovskiy, Daniil
    Jung, Kyung Hae
    Dumas, Olivier
    Penkov, Konstantin
    Dechaphunkul, Arunee
    Oaknin, Ana
    Kim, Seung Tae
    Starling, Naureen
    Chewaskulyong, Busyamas
    Charonpongsuntorn, Chanchai
    Doroshow, Deborah Blythe
    Hsiao, Sheng-Yen
    Hung, Yi-Ping
    Jung, Lindsey
    Kuptsova-Clarkson, Nataliya
    Michelini, Flavia
    Puvvada, Soham D.
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Liu, Yali
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Baselga, Jose
    Krop, Ian E.
    CANCER RESEARCH, 2021, 81 (04)
  • [8] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Fuchs, C.
    Shahidi, J.
    Mathew, L.
    Qin, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S150 - S150
  • [9] Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
    Bartsch, R.
    Berghoff, A. S.
    Furtner, J.
    Marhold, M.
    Bergen, E. S.
    Roider-Schur, S.
    Starzer, A. M.
    Forstner, H.
    Rottenmanner, B.
    Dieckmann, K.
    Bago-Horvath, Z. A.
    Widhalm, G.
    Ilhan-Mutlu, A.
    Minichsdorfer, C.
    Fuereder, T.
    Singer, C. F.
    Weltermann, A.
    Puhr, R.
    Preusser, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S198 - S198
  • [10] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
    Nozawa, Kazuki
    Kusudo, Maho
    Kureyama, Nari
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
12345